CGON Stock Analysis: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$79.81
2.20 (2.83%)
▲
5d:
+6.37%
30d:
+12.22%
90d:
+23.56%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGON shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGON shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $79.81, which is considered extended relative to its 30-day fair value range of $70.31 to $76.72.
Technical Outlook: Technically, CGON is in a uptrend. The price is approaching resistance at $80.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CGON scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.08 (+14.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGON is in a uptrend. The price is approaching resistance at $80.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CGON scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.08 (+14.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$70.31 -
$76.72
Company Quality Score
39/100
(SELL)
Options IV Signal
35th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 35th percentile)
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($91.08)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$70.31 -
$76.72
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$9.17
(11.5%)
Support & Resistance Levels
Support Level
$73.50
Resistance Level
$80.97
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.42
Wall Street Target
$91.08
(+14.1%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: August 22, 2026 5:32 PM ET
Data refreshes hourly during market hours. Next update: 6:32 PM
Data refreshes hourly during market hours. Next update: 6:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
James Mulay
SELL
1964 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
